System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Lorenzo Belluomini is an expert in Oncology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). As of October 2026, ScienceLeadR ranks Lorenzo Belluomini in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Lorenzo Belluomini has authored 152 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 9 of them ongoing. SLR score: 663 (community average: 125). How the SLR is computed.

LeadR Profile

Lorenzo Belluomini Azienda Ospedaliera Universitaria Integrata Verona Italy
663 ScienceLeadR Reputation 663

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2015 - 2026
Source: PubMed

University of Verona

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 152

Citations

Citations: 826 1st author: 22 Last author: 10 Unique author: 0

Main journals

Ann Oncol 22
Crit Rev Oncol Hematol 11
Front Oncol 8
ESMO Open 5
Expert Rev Anticancer Ther 5

Best Journals

Ann Oncol 14
J Clin Oncol 5
Cancer Cell 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lung Cancer Survivorship: Challenges and Care Needs.
PMID 42738376 — lung, neoplasms, lung neoplasms, survivorship, therapeutics, palliative care		Cancers (Basel)20260
AI-HOPE lung cancer: a multicenter real-world registry integrating artificial intelligence for metastatic non-small-cell lung cancer.
PMID 42597794 — registries, cells, intelligence, lung, tomography, positron-emission tomography, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, artificial intelligence		ESMO Real World Data Digit Oncol20260
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).
PMID 42502985 — neoplasms, carcinoma, non-small-cell lung, therapeutics, tissues		Oncologist20260
Interleukin-8 in health and disease.
PMID 42423773 — cells, pathology, interleukin-8, liver, biomarkers, sepsis, diagnosis		Mol Biomed20261
Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].
PMID 42364389 — pemetrexed, lung, neoplasms, lung neoplasms		Eur J Cancer20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
Phase 2 3
N/A 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Recruiting 7
Active not recruiting 2
Not yet recruiting 1
Suspended 1

By type:

Interventional 11

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
DAREON Lung 1 A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab carboplatin and etoposide treatment with standard chemotherapy
2025-520565-51-00 — cells, lung, neoplasms, multiple chronic conditions, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, etoposide, carboplatin, chemotherapy		Phase 3Not yet recruiting2026
A Study of Navlimetostat (BMS 986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First line Metastatic Non small Cell Lung Cancer with Homozygous MTAP Deletion
2025-521511-40-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, chemotherapy		Phase 2/Phase 3Recruiting2025
Continued PD L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first line platinum etoposide chemotherapy and a PD L1 inhibitor CARRY ON study GOIRC 01 2023
2024-511945-20-00 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, etoposide, chemotherapy		Phase 2Recruiting2025
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI ) as maintenance therapy in ctDNA positive NSCLC
2024-519262-42-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, maintenance, lung neoplasms, small cell lung carcinoma, therapeutics		Phase 2Recruiting2025
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, chemotherapy, adjuvant, small cell lung carcinoma, therapeutics, chemotherapy, carcinoma		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS